These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 16862164

  • 1. Muromonab-CD3 (Orthoclone OKT3), methylprednisolone and cyclosporine for acute graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation.
    Benekli M, Hahn T, Williams BT, Cooper M, Roy HN, Wallace P, Stewart C, Bambach B, McCarthy PL.
    Bone Marrow Transplant; 2006 Sep; 38(5):365-70. PubMed ID: 16862164
    [Abstract] [Full Text] [Related]

  • 2. Graft-versus-host-disease prophylaxis for matched unrelated donor bone marrow transplantation: comparison between cyclosporine-methotrexate and cyclosporine-methotrexate-methylprednisolone.
    Leelasiri A, Greer JP, Stein RS, Goodman S, Brandt SA, Edwards JR, Wolff SN.
    Bone Marrow Transplant; 1995 Mar; 15(3):401-5. PubMed ID: 7599565
    [Abstract] [Full Text] [Related]

  • 3. Microangiopathy following allogeneic marrow transplantation. Association with cyclosporine and methylprednisolone for graft-versus-host disease prophylaxis.
    Kalhs P, Brugger S, Schwarzinger I, Greinix HT, Keil F, Kyrle PA, Knöbl P, Schneider B, Höcker P, Linkesch W.
    Transplantation; 1995 Nov 15; 60(9):949-57. PubMed ID: 7491699
    [Abstract] [Full Text] [Related]

  • 4. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M, Perrin MC, Belhabri A, Molina L, Nicolini F, Tigaud JD, Sotto JJ, Guyotat D, Fière D, Archimbaud E.
    Bone Marrow Transplant; 1999 Jan 15; 23(2):145-50. PubMed ID: 10197799
    [Abstract] [Full Text] [Related]

  • 5. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies.
    Hebart H, Ehninger G, Schmidt H, Berner B, Reuss-Borst M, Waller HD, Müller CA, Einsele H.
    Bone Marrow Transplant; 1995 Jun 15; 15(6):891-4. PubMed ID: 7581087
    [Abstract] [Full Text] [Related]

  • 6. Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan.
    Koga Y, Nagatoshi Y, Kawano Y, Okamura J.
    Bone Marrow Transplant; 2003 Jul 15; 32(2):171-6. PubMed ID: 12838282
    [Abstract] [Full Text] [Related]

  • 7. Cyclosporine and methylprednisolone after allogeneic marrow transplantation: association between low cyclosporine concentration and risk of acute graft-versus-host disease.
    Przepiorka D, Shapiro S, Schwinghammer TL, Bloom EJ, Rosenfeld CS, Shadduck RK, Venkataramanan R.
    Bone Marrow Transplant; 1991 Jun 15; 7(6):461-5. PubMed ID: 1873593
    [Abstract] [Full Text] [Related]

  • 8. [Clinical study of a new protocol for acute graft-versus host disease prophylaxis in HLA-haploidentical bone marrow transplantation (BMT)].
    Ji SQ, Chen HR, Wang HX, Yan HM, Liu J, Xue M, Zhu L.
    Zhonghua Xue Ye Xue Za Zhi; 2003 Aug 15; 24(8):416-9. PubMed ID: 14642179
    [Abstract] [Full Text] [Related]

  • 9. Do corticosteroids add any benefit to standard GVHD prophylaxis in allogeneic BMT?
    Ancín I, Ferrá C, Gallardo D, Peris J, Berlanga J, Gonzalez JR, Virgili N, Grañena A.
    Bone Marrow Transplant; 2001 Jul 15; 28(1):39-45. PubMed ID: 11498742
    [Abstract] [Full Text] [Related]

  • 10. Prevention of graft-versus-host disease with anti-CD5 ricin A chain immunotoxin after CD3-depleted HLA-nonidentical marrow transplantation in pediatric leukemia patients.
    Przepiorka D, Chan KW, Champlin RE, Culbert SJ, Petropoulos D, Ippoliti C, Khouri I, Huh YO, Vreisendorp H, Deisseroth AB.
    Bone Marrow Transplant; 1995 Dec 15; 16(6):737-41. PubMed ID: 8750262
    [Abstract] [Full Text] [Related]

  • 11. Addition of low-dose folinic acid to a methotrexate/cyclosporin A regimen for prevention of acute graft-versus-host disease.
    Russell JA, Woodman RC, Poon MC, Jones AR, Ruether BA.
    Bone Marrow Transplant; 1994 Sep 15; 14(3):397-401. PubMed ID: 7994261
    [Abstract] [Full Text] [Related]

  • 12. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.
    Weisdorf D, Filipovich A, McGlave P, Ramsay N, Kersey J, Miller W, Blazar B.
    Bone Marrow Transplant; 1993 Nov 15; 12(5):531-6. PubMed ID: 8298565
    [Abstract] [Full Text] [Related]

  • 13. Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation.
    Malard F, Szydlo RM, Brissot E, Chevallier P, Guillaume T, Delaunay J, Ayari S, Dubruille V, Le Gouill S, Mahe B, Gastinne T, Blin N, Saulquin B, Harousseau JL, Moreau P, Mohty M.
    Biol Blood Marrow Transplant; 2010 Jan 15; 16(1):28-34. PubMed ID: 20053329
    [Abstract] [Full Text] [Related]

  • 14. Prophylaxis of graft-versus-host disease in identical sibling donor bone marrow transplant by anti-IL-2 receptor monoclonal antibody LO-Tact-1.
    Ferrant A, Latinne D, Bazin H, Straetmans N, Cornet A, de la Parra B, Michaux JL.
    Bone Marrow Transplant; 1995 Oct 15; 16(4):577-81. PubMed ID: 8528175
    [Abstract] [Full Text] [Related]

  • 15. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ, Min WS, Cho BS, Eom KS, Kim YJ, Min CK, Lee S, Cho SG, Jin JY, Lee JW, Kim CC.
    Biol Blood Marrow Transplant; 2009 Jun 15; 15(6):704-17. PubMed ID: 19450755
    [Abstract] [Full Text] [Related]

  • 16. Relationship between CsA trough blood concentration and severity of acute graft-versus-host disease after paediatric stem cell transplantation from matched-sibling or unrelated donors.
    Martin P, Bleyzac N, Souillet G, Galambrun C, Bertrand Y, Maire PH, Jelliffe RW, Aulagner G.
    Bone Marrow Transplant; 2003 Oct 15; 32(8):777-84. PubMed ID: 14520421
    [Abstract] [Full Text] [Related]

  • 17. Early (day -7) versus conventional (day -1) inception of cyclosporine-A for graft-versus-host disease prophylaxis after unrelated donor hematopoietic stem cell transplantation in children. Long-term results of an AIEOP prospective, randomized study.
    Lanino E, Rondelli R, Locatelli F, Messina C, Pession A, Balduzzi A, Favre C, Santarone S, Rabusin M, Pollichieni S, Cesaro S, Dini G, Franca Fagioli for the AIEOP-HSCT Group.
    Biol Blood Marrow Transplant; 2009 Jun 15; 15(6):741-8. PubMed ID: 19450759
    [Abstract] [Full Text] [Related]

  • 18. Continuous infusion cyclosporine and nifedipine to day +100 with short methotrexate and steroids as GVHD prophylaxis in unrelated donor transplants.
    Liesveld J, Duerst R, Rapoport A, Constine L, Abboud C, Packman C, Wedow L, Zwetsch L, McKenna B, Linder T, Silverman W, Swift S, Rowe J, DiPersio J.
    Bone Marrow Transplant; 1999 Sep 15; 24(5):511-6. PubMed ID: 10482935
    [Abstract] [Full Text] [Related]

  • 19. Cyclosporine combined with methylprednisolone or methotrexate in prophylaxis of moderate to severe acute graft-versus-host disease.
    Gondo H, Harada M, Taniguchi S, Akashi K, Hayashi S, Teshima T, Takamatsu Y, Eto T, Nagafuji K, Yamasaki K.
    Bone Marrow Transplant; 1993 Nov 15; 12(5):437-41. PubMed ID: 8298553
    [Abstract] [Full Text] [Related]

  • 20. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
    Ogawa H, Ikegame K, Yoshihara S, Kawakami M, Fujioka T, Masuda T, Taniguchi Y, Hasei H, Kaida K, Inoue T, Kim EH, Kawase I.
    Biol Blood Marrow Transplant; 2006 Oct 15; 12(10):1073-84. PubMed ID: 17084371
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.